Drug Profile
BLI 1401
Alternative Names: ABV 1501; ABV 1702; ABV 1703; ABV-1519; BLEX-404; BLI 1301; BLI-1401; BLI-1401-2Latest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator BioLite Inc
- Developer ABVC BioPharma; BioLite Inc; Cedars-Sinai Medical Center; Taipei Veterans General Hospital
- Class Antineoplastics; Beta Glucans
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Triple negative breast cancer
- Clinical Phase Unknown Myelodysplastic syndromes
- Preclinical Non-small cell lung cancer; Pancreatic cancer
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 17 Apr 2024 ABVC Biopharma and its affiliate Rgene Corporation enters into a licensing agreement with OncoX for BLI 1401 for the treatment of non-small cell lung cancer
- 27 Feb 2024 ABVC BioPharma plans to initiate a clinical trial in USA and Asia
- 04 Jan 2024 Taiwan FDA approves IND application for BLI 1401 in Non-small cell lung cancer